A 16-week, randomised, controlled, open label, multicentre, multinational, three-arm, parallel, treat-to target trial comparing efficacy and safety of three different dosing regimens of either SIBA or insulin glargine (Lantus) administered as once daily basal-bolus insulin all in combination with standard pre-meal bolus insulin in subjects with type 1 diabetes mellitus currently well controlled on basal bolus insulin regimens
Latest Information Update: 16 Jun 2016
Price :
$35 *
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 21 Aug 2010 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
- 23 Jul 2010 New trial record